"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.
about
Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphomaThe sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysisHelicobacter pylori and pregnancy-related disorders.Hematologic manifestations of Helicobacter pylori infectionEvaluation of the benefit of addition of clidinium C to a Helicobacter pylori eradication regimen.Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensusGastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.Second-line rescue therapy of helicobacter pylori infection.Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.Helicobacter pylori therapy: Present and futureLevofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation.Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)."Rescue" regimens after Helicobacter pylori treatment failure.The sequential therapy regimen for Helicobacter pylori eradication.Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.Guidelines for treatment of Helicobacter pylori in the East and West.Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma.Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphomaTreatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed?Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis.Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.Helicobacter pylori infection and gastroesophageal cancer: unveiling a Hamletic dilemma.First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy.New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China.Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer.Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China.Whole-genome sequencing of clarithromycin resistant Helicobacter pylori characterizes unidentified variants of multidrug resistant efflux pump genes.Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy.Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.Low efficacy of clarithromycin including sequential regimens for Helicobacter pylori infection.Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care.
P2860
Q26851987-AED978F2-5D43-437B-B7EF-77F4A03F60E2Q33287535-392C0D17-92B8-4656-9157-FE4EF38CB256Q33413540-88FC217A-165F-4E36-AAB5-4E60AE0DF25AQ33417972-26FB8A3F-E8C8-4A0A-BB5F-22E717ED043DQ33596607-1082A348-3F63-42E7-875E-F44918730516Q34067951-4BA00294-9F3C-4E81-BE31-74526CCBFF2BQ34389619-60859558-1EDE-4F7F-98C9-9D38B63ECE01Q34409114-7A96A48E-8610-4BA0-B151-EB7C804ACF96Q35841617-54F04A16-29FB-445B-9165-0783C9ACF578Q36215547-16FDE1C0-C550-46B8-9B2C-EB2985F8980FQ36220182-929C4A59-9FBF-459B-BD4E-5652CCCF2637Q36357419-FDCBC238-4698-40D0-8F05-2DB501A23CE4Q36410382-E2C373DC-6A0B-4AC6-A1E2-E7B6BEB3CE5CQ37123605-0EE63D4F-611F-46B7-8B4D-EFF0618E6351Q37273653-3896DF8A-0C27-43B4-A083-DB9153FDC3A9Q37703245-A059BB1F-24A6-4483-886F-B81EE0AEBDF0Q37899929-14C1FAD1-EF8E-43D0-8303-9449860EDBEFQ37912220-EB5CA3E5-C32D-430A-AFAE-1185911F03BEQ37932613-FE1286B9-7AE3-479C-A2CF-F987186F6F14Q37948164-9DE09DFF-1FF7-4AFD-881A-5B16F2D5A47AQ37963008-00F0102B-5BD4-4444-82DE-7325C4D8FF6EQ38100784-37CFD774-6F69-41AE-A6D6-832D8A68AFE0Q38101527-A8900CF7-1C34-4C3A-A7E5-755E2AEDFFDAQ38150281-9760A256-7AA6-4D87-8122-AC7063E4857EQ38194611-EC990930-B41F-4F70-891E-3835A4FF7F08Q38266303-72D247B6-AD77-4DEC-9C0E-1E6AB58BE1B7Q39503264-AF2F4635-3A1C-44D0-A494-60A34748C359Q39588933-E12CBF05-B491-4B32-9CA7-CE4386984382Q41173895-C1AFC9A1-A782-402E-AC03-AEE3FDF7D462Q41391795-9B18ACA0-E9A8-4D3B-BE68-9053187EBCC8Q41694363-EA6D03AC-6814-4FE1-AAAE-3EECA0A76E30Q41694687-445659E3-B55A-4283-A8EB-E9473960C7D7Q41745727-BF0CF8C2-E62A-4BFF-8659-0D720B0518AFQ42217403-B4D3549B-8A15-47DB-831A-8F4805F6D457Q42274547-D7999F2A-12EB-4F81-9CAE-996BE698FED6Q42718660-E2D2B51E-FEB6-4EC9-A3E3-6CAC2F4DF09BQ44200362-28BAF00B-6879-4933-BCC4-3D48F7D41F2DQ44224887-FF5A5402-499E-4882-8EC3-48A7023284E1Q45895050-D081D005-A4E2-4BB2-A528-19A59921B2FBQ45899590-77124E03-6E9C-4E07-9423-C6534F78E34B
P2860
"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
"Cervia II Working Group Repor ...... ter pylori infection in Italy.
@en
type
label
"Cervia II Working Group Repor ...... ter pylori infection in Italy.
@en
prefLabel
"Cervia II Working Group Repor ...... ter pylori infection in Italy.
@en
P2093
P50
P1476
"Cervia II Working Group Repor ...... cter pylori infection in Italy
@en
P2093
D Sorrentino
G Gasbarrini
Working Group of the Cervia II Meeting
P304
P356
10.1016/J.DLD.2007.05.016
P577
2007-07-02T00:00:00Z